Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St’s investing ideas for FREE.

• If you are wondering whether Travere Therapeutics at around US$27.82 still offers value, you are not alone, many investors are asking the same question as the stock has been on the radar of biotech focused portfolios.

• The share price has been volatile recently, with a 7.5% decline over the last week, a roughly flat 30 day return of 0.2% decline, a 29.6% year to date decline, but a 21.4% gain over 1 year and 56.1% over 3 years, while sitting slightly lower over 5 years at a 6.0% decline.

• These mixed returns have come alongside ongoing interest in Travere Therapeutics as a US focused pharmaceuticals and biotech…